Novartis Pharma AG: Novartis PluvictoTM shows statistically

Ad hoc announcement pursuant to Art. 53 LR Phase III PSMAfore trial with PluvictoTM met the primary endpoint of radiographic progression-free survival (rPFS) in PSMA-positive mCRPC who have been treated

Related Keywords

United States , New Jersey , United Kingdom , Indiana , Millburn , Highland , Canada , Switzerland , Crawford , South Lanarkshire , America , Canadian , Great Britain , American , Shreeram Aradhye , Richard Jarvis , Isabella Zinck , Michael Meo , Satoshi Sugimoto , Nicole Zinsli Somm , Samir Shah , Parag Mahanti , Julie Masow , Sloan Simpson , Mary Carmichael , Twitter , Elsevier Inc , International Prospective , Novartis , Us National Library Of Medicine , Novartis Pharmaceuticals , Committee For Medicinal Products Human Use , American Cancer Society , Accelerator Applications United States Inc , Drug Administration , Regulatory Agency , Exchange Commission , Global Drug Development , European Medicines Agency , Health Canada , Chief Medical Officer , United States Food , Medicinal Products , Human Use , Prostate Cancer , Radioligand Therapy , Phenotypic Precision Medicine , Advanced Prostate , Metastatic Castration Resistant Prostate , Survival Rates , Metastatic Prostate , Radiographic Progression Free Survival , Sequential Treatment Using Abiraterone , Propensity Score Matched Analysis , Advanced Accelerator Applications United States , Accelerator Applications United States , Receptor Directed Therapy , Combination With Soc , Versus Soc Alone , Adult Male Patients With , Clinical Radiation , Nucl Med , Dharma , Pluvicto , Shows , Statistically , Significant , Linically , Meaningful , Radiographic , Progression , Tree , Survival , Benefit , Patients , Visma , Positive , Metastatic , Castration , Resistant , Prostate ,